Charlie Jacques, APRN
Nurse Practitioner · St George, UTNPI 1336162890
Payments from drug & device makers
Across 242 payments — averaging $14.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$741
- Lilly USA, LLC$602
- Novo Nordisk$541
- BETA Bionics, Inc.$207
- Tandem Diabetes Care, Inc.$142
- Boehringer Ingelheim$141
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,533100%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 54 | $741 |
| Lilly USA, LLC | 42 | $602 |
| Novo Nordisk | 58 | $541 |
| BETA Bionics, Inc. | 13 | $207 |
| Tandem Diabetes Care, Inc. | 8 | $142 |
| Boehringer Ingelheim | 8 | $141 |
| Dexcom, Inc. | 8 | $133 |
| Radius Health, Inc. | 7 | $131 |
| Amgen | 5 | $103 |
| Novartis | 4 | $98 |
| Chiesi USA, Inc. | 4 | $94 |
| AstraZeneca(2 entities) | 5 | $93 |
| Sequel Med Tech, LLC | 3 | $82 |
| Xeris Pharmaceuticals, Inc. | 4 | $81 |
| Sanofi-aventis U.S. LLC | 2 | $54 |
| Bayer | 3 | $42 |
| Neurocrine Biosciences, Inc. | 1 | $37 |
| Ipsen Biopharmaceuticals, Inc | 1 | $20 |
| Recordati_rare_diseases_inc. | 1 | $20 |
| GRT US Holding, Inc. | 1 | $20 |
| Ascendis Pharma Endocrinology Inc | 1 | $19 |
| Ascensia Diabetes Care US Inc. | 1 | $19 |
| Insulet Corporation | 1 | $17 |
| Amryt Pharma Holdings Ltd | 1 | $16 |
| RGH Enterprises LLC | 1 | $16 |
| Halozyme Inc | 1 | $15 |
| IBSA Pharma Inc. | 1 | $15 |
| Medtronic | 1 | $15 |
| Acella Pharmaceuticals, LLC | 1 | $13 |
| Corcept Therapeutics | 1 | $13 |
How this compares
$3,542 in reported general payments places this provider in the 90th percentile of 979 nurse practitioner providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 213 | $270,331 |
| MounjaroTirzepatide | 197 | $238,405 |
| TrulicityDulaglutide | 101 | $123,048 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 71 | $113,534 |
| Humalog Kwikpen U-200Insulin Lispro | 47 | $84,060 |
| Tresiba Flextouch U-200Insulin Degludec | 44 | $79,830 |
| JardianceEmpagliflozin | 66 | $78,817 |
| Tresiba Flextouch U-100Insulin Degludec | 80 | $62,467 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 26 | $44,887 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 81 | $42,626 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $39,181 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 38 | $36,097 |
| Humalog Kwikpen U-100Insulin Lispro | 116 | $35,311 |
| Novolog FlexpenInsulin Aspart | 125 | $34,177 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 209 | $34,086 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro | $602 | $365,213324 claims |
| Novo NordiskOzempic | $541 | $270,331213 claims |
| Boehringer IngelheimJardiance, Tradjenta | $141 | $94,64889 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 979 nurse practitioner providers in Utah.
Other nurse practitioner in St George
- Brookanne MickelsonSt George$5K
- Alana BradburySt George$5K
- David GambleAmerican Fork$836K
- Julia BattenSalt Lake City$223K
- Stacie EganOgden$170K
- Traci AndreasonLehi$161K
- Geoffrey OsmondDraper$62K
- Trenton GraySouth Salt Lake$40K
- Kelsey FurrWest Jordan$21K
- Merin KinikiniSalt Lake City$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.